Add-on Acquisition • Medical Products

DiaSorin Acquires Luminex

On April 12, 2021, DiaSorin acquired medical products company Luminex for 1.8B USD

Acquisition Context

This is DiaSorin’s 1st transaction in the Medical Products sector.
This is DiaSorin’s largest (disclosed) transaction.
This is DiaSorin’s 2nd transaction in the United States.
This is DiaSorin’s 1st transaction in Texas.

Explore All 2731 Add-on Acquisition Medical Products Deals - Search the Database Free

M&A Deal Summary
Date	April 12, 2021
Target	Luminex
Sector	Medical Products
Buyer(s)	DiaSorin
Deal Type	Add-on Acquisition
Deal Value	1.8B USD
Advisor(s)	Perella Weinberg Partners (Financial) DLA Piper (Legal)

Target Company

Luminex

Austin, Texas, United States

Luminex is a developer, manufacturer and marketer of proprietary instruments and assays utilizing xMAP open-architecture, multi-analyte platform and MultiCode real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex was founded in 1995 and is based in Austin, Texas.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

DiaSorin

Saluggia, Italy

Category	Company
Founded	1968
Sector	Healthcare Services
Employees	3,184
Revenue	1.2B EUR (2024)

DESCRIPTION

DiaSorin has been developing, producing and marketing reagent kits for in vitro diagnostics worldwide. DiaSorin was founded in 1968 and is based in Saluggia, Italy.

Deal Context for Buyer	#
Overall	2 of 2
Sector: Medical Products	1 of 1
Type: Add-on Acquisition	1 of 1
State: Texas	1 of 1
Country: United States	2 of 2
Year: 2021	1 of 1
Size (of disclosed)	1 of 2

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2016-03-30	Focus Diagnostics Cypress, California, United States Focus Diagnostics, Inc. is a developer of immunodiagnostic and molecular diagnostic products.	Buy	$300M

DATE

TARGET

DEAL TYPE

VALUE

2016-03-30

Focus Diagnostics

Cypress, California, United States

Focus Diagnostics, Inc. is a developer of immunodiagnostic and molecular diagnostic products.

Buy

$300M

Explore Related M&A Activity

Medical Products M&A - Add-on Acquisition M&A Deals - Texas M&A - United States M&A - 2021 M&A